Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ETDRS Panretinal Photocoagulation (PRP) Combined With Intravitreal Ranibizumab (IVR) Versus Retinal Photocoagulation Targeted to Ischemic Retina Combined With IVR for the Treatment of Proliferative Diabetic Retinopathy
Brief Summary: Purpose: To compare panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab (IVR) (ETDRS-PRP group) and retinal photocoagulation targeted to ischemic retina combined with IVR (ISQ-RP group) in patients with proliferative diabetic retinopathy (PDR).

Design: Randomized prospective clinical trial. Methods: Patients with PDR were assigned to receive either PRP plus IVR (20 eyes) or retinal photocoagulation targeted to ischemic areas plus IVR (20 eyes). ETDRS best-corrected visual acuity (BCVA), central subfield macular thickness (CSFT) measured by optical coherence tomography (OCT) were performed at baseline and every 4 weeks through week 48. Area of fluorescein leakage from active new vessels (FLA) was measured every 12 weeks. Full-field electroretinography (ERG) was recorded at baseline and after 3 months.


Options:
A: Arm Label: ETDRS-PRP group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ETDRS-PRP group | Arm Label: ISQ-RP group; Type: EXPERIMENTAL; Interventions: Procedure: ISQ-RP | Intervention Type: PROCEDURE; Name: ISQ-RP; Assigned to Arm(s): ISQ-RP group | Intervention Type: PROCEDURE; Name: ETDRS-PRP group; Assigned to Arm(s): ETDRS-PRP group
B: Arm Label: Anti-VEGF+Deferred PRP; Type: EXPERIMENTAL; Interventions: Drug: 0.5-mg Ranibizumab, Other: Deferred panretinal photocoagulation | Arm Label: Prompt PRP; Type: ACTIVE_COMPARATOR; Interventions: Other: Prompt Panretinal Photocoagulation | Intervention Type: OTHER; Name: Prompt Panretinal Photocoagulation; Assigned to Arm(s): Prompt PRP | Intervention Type: DRUG; Name: 0.5-mg Ranibizumab; Assigned to Arm(s): Anti-VEGF+Deferred PRP | Intervention Type: OTHER; Name: Deferred panretinal photocoagulation; Assigned to Arm(s): Anti-VEGF+Deferred PRP
C: Arm Label: Panretinal photocoagulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Panretinal photocoagulation | Arm Label: Bevacizumab + Panretinal Photocoagulation (PRP); Type: EXPERIMENTAL; Interventions: Procedure: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab | Intervention Type: PROCEDURE; Name: Panretinal photocoagulation; Assigned to Arm(s): Panretinal photocoagulation | Intervention Type: PROCEDURE; Name: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab; Assigned to Arm(s): Bevacizumab + Panretinal Photocoagulation (PRP)
D: Arm Label: Intravitreous 2 mg aflibercept injections; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2-mg Intravitreous Aflibercept Injection | Arm Label: Prompt vitrectomy plus panretinal photocoagulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Prompt Vitrectomy Plus Panretinal Photocoagulation | Intervention Type: DRUG; Name: 2-mg Intravitreous Aflibercept Injection; Assigned to Arm(s): Intravitreous 2 mg aflibercept injections | Intervention Type: PROCEDURE; Name: Prompt Vitrectomy Plus Panretinal Photocoagulation; Assigned to Arm(s): Prompt vitrectomy plus panretinal photocoagulation

Answer: A